Skip to main content
SpringerLink
Log in

Lumiracoxib

A Viewpoint by Hyman Tannenbaum

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marshall PJ, Berry C, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 [abstract no. SAT0013]. Ann Rheum Dis 2002; 61 Suppl. 1: 259

    Google Scholar 

  2. Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. Epub 2004 Feb 27

  3. Bitner M, Kattenhorn J, Hatfield C, et al. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract 2004 Apr; 58(4): 340–5

    Article  PubMed  CAS  Google Scholar 

  4. Pavelka K, Nayiager S, Kivitz A, et al. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study [abstract no. FRI10107]. Ann Rheum Dis 2004 Jul; 63 Suppl. 1: 280

    Google Scholar 

  5. Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1189–98

    Article  PubMed  CAS  Google Scholar 

  6. Hawkey CJ, Karateev D, Codreanu C, et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients [abstract no. THU0226]. Ann Rheum Dis 2002; 61 Suppl. 1: 126

    Google Scholar 

  7. Schnitzer TM, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 665–74

    Article  PubMed  CAS  Google Scholar 

  8. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 675–84

    Article  PubMed  CAS  Google Scholar 

  9. Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2004; 51(4): 549–57

    Article  Google Scholar 

  10. Geusens P, Alten R, Rovensky J, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: results of a randomized double-blind study [abstract no. 544]. Arthritis Rheum 2003; 48 (9 Suppl.): 242

    Google Scholar 

  11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000 Nov 23; 343(21): 1520–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, McGill University, Montreal General Hospital, Montreal, Quebec, Canada

    Hyman Tannenbaum

Authors
  1. Hyman Tannenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tannenbaum, H. Lumiracoxib. Drugs 64, 2247–2248 (2004). https://doi.org/10.2165/00003495-200464190-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464190-00010

Search

Navigation